Cargando…

DNA therapeutics: a feasible option for treatment of inflammatory diseases?

Detalles Bibliográficos
Autor principal:	Wagner, E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2001
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273208/ http://dx.doi.org/10.1186/ar154

Ejemplares similares

Radical pancreaticoduodenectomy in elderly patients: a feasible and adequate therapeutic option?
por: Garavoglia, Marcello, et al.
Publicado: (2013)

Polypharmacy in schizophrenia - therapeutic option or a sign of despair?
por: Konstantinidis, Anastasios
Publicado: (2010)

EHMTI-0273. Onabotulinotoxin type A is a therapeutic option in chronic cluster headache
por: Mas-Sala, N, et al.
Publicado: (2014)

EHMTI-0141. URB937 as a potential therapeutic option for migraine: evaluation in animal model of migraine
por: Greco, R, et al.
Publicado: (2014)

CSII treatment as an option in high-risk pregnant patients with type 1 diabetes
por: Breder, Íkaro Soares Santos, et al.
Publicado: (2015)

Can we swallow the idea of azathioprine as the next treatment option for pediatric eosinophilic esophagitis?
por: Lall, Priyanka
Publicado: (2015)

Flexible screening clinics: future options
por: Dyson, SA, et al.
Publicado: (2000)

TAo TAVI + OPCABG: a new hybrid option
por: Brazier, Andrew, et al.
Publicado: (2015)

Feasibility of FUS lung cancer treatment using unilateral lung flooding
por: Wolfram, Frank, et al.
Publicado: (2014)

Self-administration of a novel subcutaneous bradykinin b(2) receptor antagonist, icatibant, as an effective treatment option in patients with hereditary angioedema
por: Santucci, Stephanie, et al.
Publicado: (2014)

Alternative treatment option for high risk surgical candidates after previous cardiac surgery: The Scottish National TAVI Programme experience
por: Giordano, Vincenzo, et al.
Publicado: (2015)

Genetic pass as a background of predictive, preventive, personalized medicine options and limitations
por: Baranov, Vladislav S
Publicado: (2014)

Immunomics in inflammatory rheumatic diseases
por: Konthur, Z, et al.
Publicado: (2004)

Recruitment and feasibility tool
por: van Leeuwen, Jasper, et al.
Publicado: (2015)

Platform process for production of monoclonal antibodies for research purposes – improvement option
por: Petersen, Joern Meidahl, et al.
Publicado: (2011)

Does the key to treat Rheumatoid nodules lie with oncology? - Is Cisplatin an option?
por: Omar, Eisha K, et al.
Publicado: (2013)

Possible options for introducing quality aspects in Activity-Based Funding pricing
por: Downie, James
Publicado: (2015)

Histopathological responses to a short term intraductal cytotoxic agent treatment: results of a feasibility study
por: Rao, J, et al.
Publicado: (2009)

Ultrasonography in pediatric inflammatory bowel diseases
por: Massimetti, Mauro, et al.
Publicado: (2014)

Radiofrequency obliteration to treat the great saphenous vein insufficiency, an option in geriatrics patients
por: Bonfiglio, B, et al.
Publicado: (2010)

Ultrasound in children and adolescents with inflammatory bowel disease
por: La Seta, Francesco, et al.
Publicado: (2014)

Genes, microbiome, diet and inflammatory bowel disease
por: Baldassano, Robert N
Publicado: (2015)

Differential expression and response to infliximab treatment of specific macrophage subsets in inflammatory synovitis
por: De Rycke, L, et al.
Publicado: (2004)

Changes in rheumatoid factor reflect the inflammatory response (CRP and ESR) to infliximab treatment
por: De Rycke, L, et al.
Publicado: (2003)

HIF-1 mediated upregulation of VEGF and VEGF-R in systemic sclerosis (SSc): Imbalance with angiostatic factors suggests VEGF as a novel option for the treatment of ischemia in patients with SSc
por: Distler, O, et al.
Publicado: (2002)

Is training in basic echocardiography feasible in junior doctors?
por: Md Noor, Julina, et al.
Publicado: (2012)

Thromboembolic tendency (TE) in IBD (inflammatory bowel disease) patients
por: Canero, A, et al.
Publicado: (2010)

Family collections for the analysis of common autoimmune disease genes in systemic rheumatic and inflammatory diseases
por: Melchers, I, et al.
Publicado: (2002)

Advantages, disadvantages and feasibility of Pay-for-Quality programs in Belgium
por: Van Herck, P, et al.
Publicado: (2010)

Feasibility and efficacy of neck dissections in patients with thyroid cancer
por: Wierzbicka, Małgorzata, et al.
Publicado: (2013)

Feasibility of a pretrial diversion pilot in Kent County, Rhode Island
por: Tomasulo, Anna F, et al.
Publicado: (2015)

Collagen Type II-Specific Autoantibodies in Chronic Inflammatory Joint Diseases
por: Burkhardt, Harald, et al.
Publicado: (2000)

Hsp90 is a viable therapeutic target in the treatment of KSHV-associated primary effusion lymphoma
por: Nayar, Utthara, et al.
Publicado: (2010)

Protected Research Information Management Environment (PRIME) provides a secure open source data management option for clinical and scientific research
por: Viangteeravat, Teeradache, et al.
Publicado: (2011)

Feasibility and advantages of normothermia in patients with acute cerebral damage: preliminary results of a prospective randomised study
por: Cormio, M, et al.
Publicado: (2001)

Feasibility of personalized primary prevention (PPP) in osteoporotic fracture management
por: Marton, Istvan
Publicado: (2014)

Therapeutic variability in the treatment of Candida colonization/infection in non-neutropenic critically ill patients
por: León, C, et al.
Publicado: (2001)

Modulation of magnesium deficiency-induced anxiety and HPA axis dysregulation by therapeutic drug treatment
por: Sartori, Simone B, et al.
Publicado: (2011)

Rapid Extrication of entrapped victims of motor vehicle accidents; a feasibility study
por: Johnsen, AS, et al.
Publicado: (2013)

Early experience of intensive postoperative unit (IPU): percutaneous tracheotomy as the first option after long-term oro-tracheal intubation
por: Azevedo F°, CF, et al.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_2v41m6llhs54egpq6fbqs0bs7p